BG108179A - Pyridazinone aldose reductase inhibitors - Google Patents

Pyridazinone aldose reductase inhibitors

Info

Publication number: BG108179A
Authority: BG; Bulgaria
Prior art keywords: diabetic; inhibitors; aldose reductase; relates; compositions
Prior art date: 2001-03-30

Application number

BG108179A

Other languages

Bulgarian (bg)

English (en)

Inventor

Banavara L. Mylari

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2003-09-17

Publication date

2004-09-30

2003-09-17 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-09-30 Publication of BG108179A publication Critical patent/BG108179A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BG108179A 2001-03-30 2003-09-17 Pyridazinone aldose reductase inhibitors BG108179A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28005101P	2001-03-30	2001-03-30
PCT/IB2002/000320 WO2002079198A1 (en)	2001-03-30	2002-01-31	Pyridazinone aldose reductase inhibitors

Publications (1)

Publication Number	Publication Date
BG108179A true BG108179A (en)	2004-09-30

Family

ID=23071435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108179A BG108179A (en)	2001-03-30	2003-09-17	Pyridazinone aldose reductase inhibitors

Country Status (44)

Country	Link
US (2)	US6579879B2 (xx)
EP (3)	EP1491541B1 (xx)
JP (1)	JP2004528319A (xx)
KR (1)	KR100586138B1 (xx)
CN (1)	CN1215067C (xx)
AP (1)	AP2002002461A0 (xx)
AR (1)	AR035798A1 (xx)
AT (3)	ATE352551T1 (xx)
AU (1)	AU2002226634B2 (xx)
BG (1)	BG108179A (xx)
BR (1)	BR0208571A (xx)
CA (1)	CA2442476A1 (xx)
CZ (1)	CZ20032563A3 (xx)
DE (3)	DE60202452C5 (xx)
DK (2)	DK1491540T3 (xx)
EA (1)	EA006023B1 (xx)
EC (1)	ECSP034671A (xx)
EE (1)	EE200300470A (xx)
ES (2)	ES2274369T3 (xx)
GE (1)	GEP20053675B (xx)
HK (1)	HK1061678A1 (xx)
HR (1)	HRP20030752A2 (xx)
HU (1)	HUP0303644A3 (xx)
IL (1)	IL156462A0 (xx)
IS (3)	IS2205B (xx)
MA (1)	MA27003A1 (xx)
MX (1)	MXPA03008850A (xx)
MY (1)	MY134304A (xx)
NO (1)	NO20034345L (xx)
NZ (1)	NZ528406A (xx)
OA (1)	OA12453A (xx)
PA (1)	PA8541801A1 (xx)
PE (1)	PE20030007A1 (xx)
PL (1)	PL365294A1 (xx)
PT (2)	PT1491540E (xx)
SI (1)	SI1373259T1 (xx)
SK (1)	SK11852003A3 (xx)
TN (1)	TNSN02037A1 (xx)
TW (1)	TWI245762B (xx)
UA (1)	UA73236C2 (xx)
UY (1)	UY27237A1 (xx)
WO (1)	WO2002079198A1 (xx)
YU (1)	YU71403A (xx)
ZA (1)	ZA200304671B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9710536A (pt)	1996-07-24	1999-08-17	Warner Lambert Co	Isobutilgaba e seus derivados para o tratamento da dor
DE60204611T2 (de) *	2001-02-28	2006-05-11	Pfizer Products Inc., Groton	Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
AU2002226634B2 (en) *	2001-03-30	2007-01-25	Pfizer Products Inc.	Pyridazinone aldose reductase inhibitors
AU761191B2 (en) *	2001-05-24	2003-05-29	Pfizer Products Inc.	Therapies for tissue damage resulting from ischemia
BR0306730A (pt)	2002-01-09	2004-12-21	Pfizer Prod Inc	Processo e intermediários para agentes antidiabéticos de piridazinona
US7419981B2 (en) *	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) *	2002-08-15	2004-05-13	Field Mark John	Synergistic combinations
US6872833B2 (en) *	2003-04-14	2005-03-29	Hoffmann-La Roche Inc.	Adenosine receptor ligands
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
AR049384A1 (es)	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
US20060035251A1 (en) *	2004-06-30	2006-02-16	Whitehead Institute For Biomedical Research	Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
EP1973876A2 (en) *	2006-01-13	2008-10-01	Wyeth	Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
EP2431367A3 (en)	2006-06-27	2012-07-04	Takeda Pharmaceutical Company Limited	Fused cyclic compounds as GPR40 receptor modulators
ES2382009T3 (es)	2006-12-01	2012-06-04	Bristol-Myers Squibb Company	Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US8173645B2 (en) *	2007-03-21	2012-05-08	Takeda San Diego, Inc.	Glucokinase activators
SG157299A1 (en)	2008-05-09	2009-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
CA2783699C (en)	2009-12-08	2019-01-15	Case Western Reserve University	Primary amine compounds for treating ocular disorders
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
TWI464147B (zh) *	2011-09-15	2014-12-11	Univ Taipei Medical	吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
US9339542B2 (en) *	2013-04-16	2016-05-17	John L Couvaras	Hypertension reducing composition
BR112015026513A2 (pt)	2013-04-17	2017-07-25	Pfizer	derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CN103739547B (zh) *	2014-01-03	2015-09-02	沈阳药科大学	2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
US20180118756A1 (en) *	2015-04-14	2018-05-03	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase activity
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
HUE064911T2 (hu)	2016-06-21	2024-04-28	Univ Columbia	4-oxo-3,4-dihidrotieno[3,4-d]piridazin vegyületek mint aldóz-reduktáz inhibitorok és felhasználási eljárásuk
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
WO2018058109A1 (en) *	2016-09-26	2018-03-29	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
US11690847B2 (en)	2016-11-30	2023-07-04	Case Western Reserve University	Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
CN118480009A (zh)	2017-02-06	2024-08-13	卡斯西部储备大学	调节短链脱氢酶活性的组合物和方法
JP7307059B2 (ja)	2017-07-28	2023-07-11	アプライドセラピューティクス，インコーポレイテッド	ガラクトース血症を処置するための組成物および方法
MX2021008533A (es)	2019-01-18	2021-08-19	Astrazeneca Ab	Inhibidores de la pcsk9 y metodos de uso de los mismos.
EP3966320A4 (en)	2019-05-07	2023-10-25	University of Miami	TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS
MX2021014441A (es)	2019-05-31	2022-01-06	Ikena Oncology Inc	Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2020243415A2 (en)	2019-05-31	2020-12-03	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2022120353A1 (en) *	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE47592B1 (en)	1977-12-29	1984-05-02	Ici Ltd	Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en)	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
US4996204A (en)	1989-05-11	1991-02-26	Pfizer Inc.	Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
EP0516860A4 (en) *	1990-11-30	1993-12-01	Tsumura & Co.	Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
BR9205810A (pt)	1991-03-28	1994-06-28	Pfizer	Acidos piridazinona acéticos
US5834466A (en)	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TW438587B (en)	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
KR20010015607A (ko) *	1997-09-24	2001-02-26	에사 헤이노넨, 마자 리타라	포스폴암밴 억제자로서 1-옥사, 아자 및티아나프탈렌-2-온의 비스에테르
FR2822827B1 (fr) *	2001-03-28	2003-05-16	Sanofi Synthelabo	Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
AU2002226634B2 (en) *	2001-03-30	2007-01-25	Pfizer Products Inc.	Pyridazinone aldose reductase inhibitors
EP1392310A1 (en) *	2001-04-30	2004-03-03	Pfizer Products Inc.	Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
BR0306730A (pt) *	2002-01-09	2004-12-21	Pfizer Prod Inc	Processo e intermediários para agentes antidiabéticos de piridazinona

2002
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 EP EP04023150A patent/EP1491541B1/en not_active Expired - Lifetime
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/en not_active Abandoned
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/en active IP Right Grant
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 EP EP02716247A patent/EP1373259B1/en not_active Expired - Lifetime
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 EP EP04023149A patent/EP1491540B1/en not_active Expired - Lifetime
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active IP Right Cessation
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-17 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
2004
- 2004-06-24 HK HK04104538A patent/HK1061678A1/xx not_active IP Right Cessation
2006
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown

Also Published As

Publication number	Publication date
TNSN02037A1 (fr)	2005-12-23
EA006023B1 (ru)	2005-08-25
GEP20053675B (en)	2005-11-25
NO20034345D0 (no)	2003-09-29
MA27003A1 (fr)	2004-12-20
DK1491540T3 (da)	2007-03-26
AP2002002461A0 (en)	2002-06-30
DE60216823D1 (de)	2007-01-25
IS6845A (is)	2003-06-16
EA200300673A1 (ru)	2003-12-25
MXPA03008850A (es)	2003-12-04
CN1215067C (zh)	2005-08-17
US6579879B2 (en)	2003-06-17
TWI245762B (en)	2005-12-21
EP1491541B1 (en)	2007-01-24
SI1373259T1 (en)	2005-04-30
IS8251A (is)	2006-01-23
ATE286049T1 (de)	2005-01-15
SK11852003A3 (sk)	2004-07-07
HRP20030752A2 (en)	2005-06-30
DK1373259T3 (da)	2005-03-29
IS8250A (is)	2006-01-23
EP1491540A1 (en)	2004-12-29
KR20030088484A (ko)	2003-11-19
MY134304A (en)	2007-12-31
DE60202452D1 (de)	2005-02-03
NZ528406A (en)	2004-03-26
EP1373259B1 (en)	2004-12-29
HK1061678A1 (en)	2004-09-30
ES2274369T3 (es)	2007-05-16
IL156462A0 (en)	2004-01-04
NO20034345L (no)	2003-09-29
CN1500087A (zh)	2004-05-26
ZA200304671B (en)	2004-06-25
ES2231681T3 (es)	2005-05-16
AU2002226634B2 (en)	2007-01-25
CA2442476A1 (en)	2002-10-10
CZ20032563A3 (cs)	2004-05-12
DE60216823T2 (de)	2007-10-04
YU71403A (sh)	2006-05-25
PA8541801A1 (es)	2002-10-28
ECSP034671A (es)	2003-08-29
US20020143017A1 (en)	2002-10-03
IS2205B (is)	2007-02-15
ATE352551T1 (de)	2007-02-15
WO2002079198A1 (en)	2002-10-10
EE200300470A (et)	2004-02-16
EP1491541A1 (en)	2004-12-29
PL365294A1 (en)	2004-12-27
HUP0303644A2 (hu)	2004-03-01
DE60217930D1 (de)	2007-03-15
OA12453A (en)	2006-05-24
DE60202452C5 (de)	2006-11-23
PT1373259E (pt)	2005-03-31
PE20030007A1 (es)	2003-01-28
DE60202452T2 (de)	2006-02-09
US6849629B2 (en)	2005-02-01
UY27237A1 (es)	2002-12-31
DE60217930T2 (de)	2007-10-18
HUP0303644A3 (en)	2008-06-30
PT1491540E (pt)	2007-01-31
EP1491540B1 (en)	2006-12-13
UA73236C2 (en)	2005-06-15
KR100586138B1 (ko)	2006-06-07
JP2004528319A (ja)	2004-09-16
ATE348100T1 (de)	2007-01-15
EP1373259A1 (en)	2004-01-02
US20030162784A1 (en)	2003-08-28
BR0208571A (pt)	2004-03-23
AR035798A1 (es)	2004-07-14

Publication	Publication Date	Title
BG108179A (en)	2004-09-30	Pyridazinone aldose reductase inhibitors
MY115288A (en)	2003-05-31	Substituted pyrimidines for control of diabetic complications.
DE60309836D1 (de)	2007-01-04	Kristalline zeolithische aluminosilikat-zusammensetzung: uzm-9
EA200100933A1 (ru)	2002-04-25	Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы
AU2006254902A8 (en)	2012-08-16	Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
MY150667A (en)	2014-02-28	Antiviral nucleosides
WO2005123672A3 (en)	2006-03-02	Kinase inhibitors
TW200607804A (en)	2006-03-01	Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
TW200613457A (en)	2006-05-01	Sulfide dyes
UA86962C2 (xx)	2009-06-10	Інгібітори вірусної полімерази$ингибиторы вирусной полимеразы
TW200609334A (en)	2006-03-16	Flame-retardants
TW200604174A (en)	2006-02-01	Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
MX2007006084A (es)	2007-07-11	Composiciones y metodos de recubrimiento.
WO2006062984A3 (en)	2006-08-31	Inhibitors of protein kinases
WO2006062982A3 (en)	2006-08-10	Urea inhibitors of map kinases
WO2004020599A3 (en)	2006-12-28	Hedgehog antagonists, methods and uses related thereto
NO20073024L (no)	2007-07-02	Kinaseinhibitorer
UA94910C2 (ru)	2011-06-25	Замещенные глицинамиды с антитромбическим действием и ингибирующим действием на фактор ха
DE60112933D1 (de)	2005-09-29	N-phenyl-4-(4-pyridyl)-2-pyrimidinamine-derivate
WO2005097701A3 (de)	2006-04-13	Hydraulisches bindemittel
WO2006028963A3 (en)	2006-11-09	Substituted heterocyclic compounds and uses thereof
BRPI0502564A (pt)	2006-02-07	Composições de aditivo e de combustìvel, uso de um componente estabilizante, e, método para melhorar a estabilidade de uma composição de aditivo de combustìvel ou de uma composição de combustìvel
CN100417741C (zh)	2008-09-10	一种铸钢材料
RU2325337C1 (ru)	2008-05-27	Стекло
BR0306730A (pt)	2004-12-21	Processo e intermediários para agentes antidiabéticos de piridazinona